Aurinia Pharmaceuticals (NASDAQ:AUPH) Issues Earnings Results

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) issued its earnings results on Tuesday. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.07, Zacks reports. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The firm had revenue of $73.47 million during the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals updated its FY 2025 guidance to EPS.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ AUPH traded up $0.11 during midday trading on Wednesday, hitting $14.38. 2,012,260 shares of the company’s stock traded hands, compared to its average volume of 1,645,122. The firm has a fifty day moving average of $12.14 and a 200 day moving average of $10.06. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of 33.28 and a beta of 1.25. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. Aurinia Pharmaceuticals has a 1 year low of $6.55 and a 1 year high of $16.20.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on AUPH shares. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $15.00 target price (up from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $16.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its position in shares of Aurinia Pharmaceuticals by 6.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 82,509 shares of the biotechnology company’s stock worth $699,000 after buying an additional 4,666 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Aurinia Pharmaceuticals by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock valued at $642,000 after buying an additional 3,497 shares during the last quarter. Osaic Holdings Inc. raised its stake in Aurinia Pharmaceuticals by 43.9% in the second quarter. Osaic Holdings Inc. now owns 34,677 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 10,585 shares during the last quarter. Brevan Howard Capital Management LP purchased a new position in shares of Aurinia Pharmaceuticals in the second quarter worth about $261,000. Finally, Corient Private Wealth LLC raised its stake in shares of Aurinia Pharmaceuticals by 57.3% in the second quarter. Corient Private Wealth LLC now owns 29,560 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 10,768 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.